Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Upadacitinib for Hidradenitis Suppurativa
Recruiting1 awardPhase 3
Toronto, Ontario
This trial will investigate the safety and effectiveness of upadacitinib in treating adults and adolescents with HS who have not responded to anti-TNF therapy. 1328 participants will be enrolled in 275 sites worldwide.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.